ClinicalTrials.gg
Not yet recruitingNCT06134414Updated Jul 29, 2025

Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 2 interventional study of MY008211A tablets in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Wuhan Createrna Science and Technology Co., Ltd. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Wuhan Createrna Science and Technology Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the efficacy of MY008211A in adult patients with PNH, showing signs of active hemolysis.

Read the detailed description

The purpose of this study is to determine whether MY008211A is efficacious and safe for the treatment of PNH patients who are naïve to complement inhibitor therapy, including anti-C5 antibody.

02

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
03

In context

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

This study's planned enrollment of 40 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.

Browse Hemoglobinuria, Paroxysmal studies →

Lead sponsor

Wuhan Createrna Science and Technology Co., Ltd is the lead sponsor of 14 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants ≥ 18 years of age and ≥ 18.0 kg/m2 with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size ≥ 10%.
  • Mean level \<100 g/L.
  • LDH > 1.5 x (ULN).
  • Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment. If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given.

Exclusion criteria

Exclusion Criteria:

  • Patients with reticulocytes \<100x10\^9/L; \<30x10\^9/L; neutrophils \<0.5x10\^9/L.
  • Were using a complement inhibitor before the first administration of MY008211A tablets or had discontinued a previous complement inhibitor for less than five half-lives or 120 days, whichever was the longest.
  • History of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus.
  • Known or suspected hereditary complement deficiency.
  • Previous bone marrow or hematopoietic stem cell transplantation.
  • Previous splenectomy.
  • A history of within 5 years before screening, except cured local basal cell carcinoma of the skin and carcinoma in situ of the cervix.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Arm 1 MY008211A low dose

    Participants will receive MY008211A at a dose of 400 mg orally b.i.d

    Drug: MY008211A tablets

  • Experimental
    Arm 2 MY008211A high dose

    Participants will receive MY008211A at a dose of 600 mg orally b.i.d

    Drug: MY008211A tablets

Interventions

  • dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization

    Also known as: MY008211A

06

What researchers measure

Primary outcomes

  1. The proportion of subjects with an increase in hemoglobin concentration ≥ 20 g/L from baseline among subjects who do not receive RBC transfusion after 4 weeks of dosing

    Proportion of participants achieving a sustained increase from baseline in hemoglobin levels of ≥ 20 g/L assessed , in the absence of red blood cell transfusions

    Time frame: Day 70

Secondary outcomes

  1. The proportion of patients with an increase in hemoglobin ≥ 20 g/L from baseline among those without RBC transfusion

    The proportion of patients with an increase in hemoglobin ≥ 20 g/L from baseline among those without RBC transfusion

    Time frame: Day14, 21, 28, 42, 56

  2. The proportion of patients with hemoglobin ≥ 120 g/L among those without RBC transfusion

    The proportion of patients with hemoglobin ≥ 120 g/L among those without RBC transfusion

    Time frame: Day14, 21, 28, 42, 56 and 70

  3. Change in hemoglobin concentration from baseline in patients without RBC transfusion

    Change in hemoglobin concentration from baseline in patients without RBC transfusion

    Time frame: Day14, 21, 28, 42, 56 and 70

  4. Change in LDH level from baseline

    Change in LDH level from baseline

    Time frame: Day7, 14, 21, 28, 42, 56 and 70

  5. The proportion of patients with hemolysis controlled

    The proportion of patients with hemolysis controlled (defined as LDH \< 1.5 ULN)

    Time frame: Day7, 14, 21, 28, 42, 56 and 70

  6. Change in reticulocyte count from baseline in patients without RBC transfusion

    Change in reticulocyte count from baseline in patients without RBC transfusion

    Time frame: Day7, 14, 21, 28, 42, 56 and 70

  7. Change in indirect bilirubin level from baseline

    Change in indirect bilirubin level from baseline

    Time frame: Day7, 14, 21, 28, 42, 56 and 70

  8. The proportion of patients without RBC transfusion

    The proportion of patients without RBC transfusion

    Time frame: Day14, 21, 28, 42, 56 and 70

  9. Change in the average weekly amount of RBC transfused during the efficacy observation period

    Change in the average weekly amount of RBC transfused during the efficacy observation period compared with that pre-dose

    Time frame: Day70

  10. Change From Baseline in FACIT-Fatigue Questionnaire

    Change from baseline in FACIT-Fatigue scores. The FACIT-Fatigue is a 13-item questionnaire with support for its validity and reliability in PNH that assesses patient self-reported fatigue and its impact on daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F Scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best.

    Time frame: Day7, 14, 21, 28, 42, 56 and 70

  11. Changes from baseline in alternative complement pathway activity

    Alternative complement pathway activity measured by the WIESLAB® kit.

    Time frame: Day14, 28, 56 and 70

  12. Change in the amount of fragment Bb of CFB in plasma from baseline

    Bb fragment cleaved by factor B of complement.

    Time frame: Day14, 28, 56 and 70

  13. Change in the level of PNH RBC clones from baseline in patients without RBC transfusion.

    Change from baseline in the level of PNH red cell clones.

    Time frame: Day70

  14. Incidence of Adverse Events (AEs) between Day 1 and Day 70

    Adverse Events (AEs)

    Time frame: Day 70

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Jul 2027, 19 months later.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's planned 19 months is above that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2023
First posted
Nov 18, 2023
StartEst.
Dec 2025
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2027
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06134414
Lead sponsor
Wuhan Createrna Science and Technology Co., Ltd
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Dec 2025 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 29, 2025

Study contacts

Xiaoni Li, Ph.D
Contact
lixiaoni@createrna.com
021-51158605

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lanoracopan

Start the discussion